Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Bin-Tao Huang"'
Publikováno v:
Arthritis Research & Therapy, Vol 22, Iss 1, Pp 1-10 (2020)
Abstract Background C-reactive protein (CRP) has two natural isomers: C-reactive protein pentamer (pCRP) and C-reactive protein monomer (mCRP). The levels of CRP are significantly elevated in patients with anti-neutrophil cytoplasmic antibody (ANCA)-
Externí odkaz:
https://doaj.org/article/1d2db6f962844ea9a58ae846a25a6c2a
[Background] C-reactive protein (CRP) has two natural isomers: C-reactive protein pentamer (pCRP) and C-reactive protein monomer (mCRP). The levels of CRP are significantly elevated in patients with anti-neutrophil cytoplasmic antibody (ANCA)-associa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3510cd4661c4f4a74f82ad0483246f4b
https://doi.org/10.21203/rs.3.rs-23451/v3
https://doi.org/10.21203/rs.3.rs-23451/v3
Publikováno v:
Arthritis Research & Therapy, Vol 22, Iss 1, Pp 1-10 (2020)
Arthritis Research & Therapy
Arthritis Research & Therapy
Background C-reactive protein (CRP) has two natural isomers: C-reactive protein pentamer (pCRP) and C-reactive protein monomer (mCRP). The levels of CRP are significantly elevated in patients with anti-neutrophil cytoplasmic antibody (ANCA)-associate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::212d256802eee624bcae90ae5804d708
https://doi.org/10.21203/rs.3.rs-23451/v2
https://doi.org/10.21203/rs.3.rs-23451/v2
Publikováno v:
Leukemia Research. 63:28-33
To determine the role and mechanism of EphB4 in dasatinib (DAS) resistance in advanced chronic myeloid leukemia (CML), we explored the EphB4-mediated apoptotic and matrix microenvironment pathway in human CML and K562 cell lines.Heparinized bone marr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::779be5a8ef140e4d6c846ae8b2ea93fc
https://doi.org/10.1016/j.leukres.2017.10.014
https://doi.org/10.1016/j.leukres.2017.10.014
Publikováno v:
Leukemia Research. 39:424-428
The open-label, prospective, observational study aimed to evaluate whether decitabine (DAC) plus thalidomide versus DAC monotherapy improved progression-free (PFS), overall survival (OS) and acute myeloid leukemia-free survival (AML-FS) for risk-tail
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eee83846944eb82f6094a18b45ff8057
https://doi.org/10.1016/j.leukres.2015.01.014
https://doi.org/10.1016/j.leukres.2015.01.014
Publikováno v:
Leukemia Research. 38:1177-1183
This open-label, prospective, observational study aimed to evaluate treatment response, efficacy therapy and safety to IFN α-2b for the essential thrombocythemia (ET) and polycythemia vera (PV) with JAK2V617F positive mutation.A total of 123 ET pati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::874000d7ec8aed9f578ea3bbd165c676
https://doi.org/10.1016/j.leukres.2014.06.019
https://doi.org/10.1016/j.leukres.2014.06.019
Publikováno v:
Journal of Cancer Research and Clinical Oncology. 140:303-309
This was an open-label, observational, prospective assessment. We conducted an analysis of the impact of bortezomib-based therapy (PAD: bortezomib, doxorubicin, high-dose dexamethasone vs. CBd: cyclophosphamide bortezomib, low-dose dexamethasone) on
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c29537b975cae84ff4ac286cc278b9b7
https://doi.org/10.1007/s00432-013-1570-6
https://doi.org/10.1007/s00432-013-1570-6
Publikováno v:
Medical oncology (Northwood, London, England). 31(10)
This open-label, prospective, observational study aimed to evaluate disease-free survival (DFS), overall survival (OS), PML–RARα polymerase chain reaction (PCR) monitoring and safety in elderly patients with de novo acute promyelocytic leukemia (A
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a52891c99b59ede65079df184fef2cb1
https://pubmed.ncbi.nlm.nih.gov/25213763
https://pubmed.ncbi.nlm.nih.gov/25213763
Publikováno v:
Medical oncology (Northwood, London, England). 31(8)
The open-label, prospective, observational study aimed to evaluate whether the addition of maintenance rituximab (MR) improved progression-free survival (PFS) and overall survival (OS), after fludarabine, cyclophosphamide, and rituximab (FCR) for cyt
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9239c8f8b36baa2aafbd2fdea9ad3be1
https://pubmed.ncbi.nlm.nih.gov/24985882
https://pubmed.ncbi.nlm.nih.gov/24985882
Publikováno v:
Medical oncology (Northwood, London, England). 31(5)
The open-label, prospective study aimed to evaluate the efficacy and safety for standard intensive chemotherapy compared with attenuated therapy in elderly patients with acute myeloid leukemia (AML). A total of 297 patients between 65 and 82 years we
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8713ee7788c7079cd46d3153033698be
https://pubmed.ncbi.nlm.nih.gov/24743870
https://pubmed.ncbi.nlm.nih.gov/24743870